Posts per subject

Pembrolizumab

Immune therapy prevents bladder removal for some bladder cancer patients

A proportion of patients with difficult-to-treat non-metastatic bladder cancer benefit from immunotherapy with the drug pembrolizumab. This has been shown by international research, which Erasmus MC Cancer Institute co-led. Annually, researchers estimate this new therapy could save about 50 patients in the Netherlands from having their bladder removed.

beeld-efficienter-gebruikk-kankermedicatie-1140×642

Oncology

More efficient cancer therapies possible: better for patient, healthcare costs, and environment

Internist and oncologist Stefan Sleijfer and hospital pharmacist Roelof van Leeuwen of Erasmus MC Cancer Institute are working closely together to make cancer therapies more effective. This is not only good for patients, but also for public coffers and for the environment. These efforts save the department of Internal Oncology about EUR 7 million per […]